AGT and Hepatic fibrosis: Changes in the balance of different angiotensin bioactive peptides (AngII, AngIII, AngIV, Ang2-10, and Ang1-7) have been implicated in different chronic diseases, such as liver fibrosis, portal hypertension, hepatic tumors [37,78,79], and metabolic alterations, whereas the blocking of angiotensin receptors has been shown to improve glycemic control and reduce hepatic triglyceride levels [80].